This study is testing two new treatments, BNT323 and BNT327, to see if they are safe and help people with advanced breast cancer. The study has two parts: Part 1 will find the best dose of the medicine, and Part 2 will see how well it works. Breast cancer is a disease where cells in the breast grow out of control. Some breast cancers are called HER2-positive because they have a lot of a protein called HER2. Others are HER2-low or HER2-null, meaning they have less of this protein.
- The study is multi-site, so it happens in different places, and participants will be randomly assigned to different groups in Part 2.
- It’s important to have a certain heart function, measured by a test, to be part of this study.
- People cannot join if they’ve had certain lung diseases or certain treatments before.
Participants will join if they have advanced breast cancer that can’t be removed by surgery or has spread to other parts. The study will help find the best dose and check if the new treatment is beneficial.
How understandable was the trial content above?
Hard to understand
Easy to understand